ClinicalTrials.gg
TerminatedNCT04817761Updated Oct 29, 2026Results posted

SPARK-ALL: Calaspargase Pegol in Adults With ALL

A Phase 2/3 interventional study of Calaspargase pegol (S95015) in Acute Lymphoblastic Leukemia, sponsored by Institut de Recherches Internationales Servier. Terminated at 21 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Institut de Recherches Internationales Servier · Phase 2/3, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision.
Updated Oct 29, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States — 168 open to participants now, 274 under way, 13 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States.

Enrollment
518th of 1,269
42 · median 35
Started
2021
with 35 others
Phase 2/3
14 of 1,545
none open now
Registered
1,325th of 1,545
by date

Among the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, this one is the 518th largest by enrollment of the 1,269 interventional ones that give a count, is one of 36 that started in 2021, is one of 14 in phase 2/3, and was the 1,325th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

168 of the 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,545 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this phase 2/3 study is to confirm the recommended doses and to evaluate the safety and pharmacodynamics of Calaspargase pegol for the treatment of adult patients with Philadelphia-negative Acute Lymphoblastic Leukemia.

Read the detailed description

The study will be conducted in 2 parts. Part 1 is a dose confirmation run-in period. Part 2 will enroll the remaining participants at the dose as confirmed or recommended in Part 1.

03

Conditions studied

  • Acute Lymphoblastic Leukemia

Keywords

  • Acute Lymphoblastic Leukemia
  • ALL
  • Ph-negative B-cell and T cell ALL
  • Philadelphia-negative ALL
  • Calaspargase Pegol
  • Asparlas
  • Adult
  • Acute Lymphocytic Leukemia
  • Newly diagnosed ALL
  • Untreated ALL
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥22 with newly-diagnosed and confirmed and documented Philadelphia-negative B-cell or T-cell ALL by World Health Organization (WHO) classification (2016).
  • performance status (ECOG PS) 0 to 2.
  • No prior therapy for ALL such as chemotherapy and radiation therapy before signing the except for limited treatment (≤7 days) with or hydroxyurea and a single dose of intrathecal cytarabine.

Exclusion criteria

Exclusion Criteria:

  • Patients with Philadelphia chromosome positive ALL, Burkitt's leukemia, mixed lineage/mixed phenotype acute leukemia, and acute undifferentiated leukemia per WHO classification (2016).
  • Patients with Down syndrome.
  • Patients with (positive for HBs antigen), and (HCV antibody) at inclusion
  • Participants known to be -positive.
  • Known history of non-gallstone-related pancreatitis.
  • Known severe hepatic impairment ( >3 x [ULN]; transaminases >5 times ULN (unless suspected leukemic involvement of the liver).
  • Pre-existing history of hepatic veno-occlusive disease (VOD).
  • > 35 kg/m2 (This criterion was introduced as an amendment for Part 2)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Calaspargase pegol (S95015)

    Drug: Calaspargase pegol (S95015)

Interventions

  • DrugCalaspargase pegolStudies of Calaspargase pegolCalaspargase pegol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed. Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen. Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2. Patients aged 40 to \< 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    Including Treatment-emergent adverse events (TEAEs), adverse events of special interests (AESI); and serious adverse events (SAEs). AEs recorded and evaluated throughout the study in accordance with NCI CTCAE criteria 5.0.

    Time frame: Through study completion, approximately 3.5 years

  2. Plasma Asparaginase Activity (PAA) Level (Part 1 and Part 2)

    Assessment of PAA in Part 1 is based on population modeling analysis.

    Time frame: 7 days, 14 days, 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and the Remission Consolidation phase (Day 36-91 post baseline)

  3. Nadir Plasma Asparaginase Activity (NPAA) (Part 2)

    Participants with NPAA level ≥0.1 U/mL 21 days after the Remission Consolidation Phase Day 43 dose.

    Time frame: Day 64 (Remission Consolidation Phase Day 36-91 post baseline).

Secondary outcomes

  1. Number of Participants With Plasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Any Time During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

    Pharmacodynamics criterion.

    Time frame: Days 4-5-6&11-18-25 (Induction, Day 0-35 PB (post baseline)); Days 15-16-43-44&22-29-36-50-57-64 (Consolidation, Day 36-91 PB); Days 22-23&29-36-43 (Maintenance, Day 92-147 PB); Days 4-5,43-44 & 11-18-25-50-57-64 (Delayed Intensification, Day 148-203 PB)

  2. Plasma Asparaginase Activity (PAA) Level ≥0.025 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

    Pharmacodynamics criterion.

    Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)

  3. Plasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

    Pharmacodynamics criterion.

    Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)

  4. Plasma Asparaginase Activity (PAA) Level ≥0.2 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

    Pharmacodynamics criterion.

    Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)

  5. Plasma Asparaginase Activity (PAA) Level ≥0.4 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

    Pharmacodynamics criterion.

    Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)

  6. PAA-derived Maximum Concentration (Cmax) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).

    PAA-derived Cmax are based on population modeling analysis.

    Time frame: From days 4-25 (Remission Induction, Day 0-35 post baseline)

  7. PAA-derived Area Under the PAA-Time Curve From Time 0 to Day 35 (AUC 0-35) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).

    PAA-derived AUC 0-35 are based on population modeling analysis.

    Time frame: From Days 0-35 (Remission Induction, Day 0-35 post baseline)

  8. Minimal Residual Disease (MRD) at End of Remission Induction (Part 1 and 2)

    Efficacy criterion. A positive result indicates that there is some disease still present. A negative result indicates that there is no disease present.

    Time frame: End of remission induction phase (Day 0-35 post baseline) (Day 29).

  9. Participants Who Achieved Complete Remission (CR) (Part 1 and 2)

    Morphologic complete remission rate (CR), morphologic complete remission rate with incomplete blood count recovery (CRi).

    Time frame: Day 29 remission induction phase (Day 0-35 post baseline)

  10. EFS (Event-free Survival) (Part 1 and 2)

    Probability estimates for EFS until 1 year, 2 years, and 3 years

    Time frame: Through study completion an average of 3.5 years

  11. DFS (Disease-free Survival) (Part 1 and 2)

    Probability estimates for DFS until 1 year, 2 years, and 3 years

    Time frame: Through study completion an average of 3.5 years

  12. OS (Overall Survival) (Part 1 and 2)

    Probability estimates for OS until 1 year, 2 years, and 3 years

    Time frame: Through study completion an average of 3.5 years

  13. Anti-drug (Calaspargase Pegol) Antibody (ADA) Development (Part 1 and 2)

    Immunogenicity criterion.

    Time frame: Through 365 (±7) days after the first dose or 30 days after the last dose if the participant discontinued

07

Results

Posted Oct 29, 2026
Limitations and caveats
The results, especially for EFS, DFS, OS and the antibody data (outcome measures 13 to 16) should be interpreted with caution due to the low number of patients by group.

Participant flow

Participant flow — Overall Study
MilestonePart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Started911688
Completed910555
Not completed01133
Withdrew: Death01132
Withdrew: Lost to follow-up00001

Outcome measures

PrimaryAdverse Events (AEs)

Including Treatment-emergent adverse events (TEAEs), adverse events of special interests (AESI); and serious adverse events (SAEs). AEs recorded and evaluated throughout the study in accordance with NCI CTCAE criteria 5.0.

Time frame:
Through study completion, approximately 3.5 years
Reported as:
Count of participants · Participants
Adverse Events (AEs)
ParticipantsPart 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)Part 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2
TEAEs688911
AESIs46676
SAEs26587
PrimaryPlasma Asparaginase Activity (PAA) Level (Part 1 and Part 2)

Assessment of PAA in Part 1 is based on population modeling analysis.

Time frame:
7 days, 14 days, 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and the Remission Consolidation phase (Day 36-91 post baseline)
Reported as:
Mean · U/mL
Plasma Asparaginase Activity (PAA) Level (Part 1 and Part 2)
U/mLPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Remission Induction - 7 Days After Last Administration0.5911 ± 0.208490.6487 ± 0.171690.4121 ± 0.185860.2398 ± 0.177430.2523 ± 0.16662
Remission Induction - 14 Days After Last Administration0.4182 ± 0.175080.3711 ± 0.271620.2651 ± 0.148100.1487 ± 0.076120.1550 ± 0.11047
Remission Induction - 21 Days After Last Administration0.2894 ± 0.146100.2702 ± 0.166740.2097 ± 0.133520.1093 ± 0.056840.0573 ± 0.04991
Remission Consolidation - 7 Days After Last Administration0.4851 ± 0.334480.8412 ± 0.420750.4835 ± 0.269770.4072 ± 0.154540.2181 ± 0.22531
Remission Consolidation - 14 Days After Last Administration0.4271 ± 0.297790.5078 ± 0.359390.3846 ± 0.210380.2282 ± 0.133210.1847 ± 0.20467
Remission Consolidation - 21 Days After Last Administration0.3318 ± 0.267910.5445 ± 0.036880.2664 ± 0.165420.1567 ± 0.087770.1125 ± 0.12338
PrimaryNadir Plasma Asparaginase Activity (NPAA) (Part 2)

Participants with NPAA level ≥0.1 U/mL 21 days after the Remission Consolidation Phase Day 43 dose.

Time frame:
Day 64 (Remission Consolidation Phase Day 36-91 post baseline).
Reported as:
Count of participants · Participants
Nadir Plasma Asparaginase Activity (NPAA) (Part 2)
ParticipantsCombined: Calaspargase Pegol (S95015) 1750 U/m2 and 1500 U/m2
Nadir Plasma Asparaginase Activity (NPAA) (Part 2)5
SecondaryNumber of Participants With Plasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Any Time During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

Pharmacodynamics criterion.

Time frame:
Days 4-5-6&11-18-25 (Induction, Day 0-35 PB (post baseline)); Days 15-16-43-44&22-29-36-50-57-64 (Consolidation, Day 36-91 PB); Days 22-23&29-36-43 (Maintenance, Day 92-147 PB); Days 4-5,43-44 & 11-18-25-50-57-64 (Delayed Intensification, Day 148-203 PB)
Reported as:
Count of participants · Participants
Number of Participants With Plasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Any Time During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
ParticipantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Number of Participants With Plasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Any Time During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)911688
SecondaryPlasma Asparaginase Activity (PAA) Level ≥0.025 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

Pharmacodynamics criterion.

Time frame:
7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
Reported as:
Count of participants · Participants
Plasma Asparaginase Activity (PAA) Level ≥0.025 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
ParticipantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Remission Induction - 7 Days After Last Administration961177
Remission Induction - 14 Days After Last Administration941155
Remission Induction - 21 Days After Last Administration95753
Remission Consolidation - Pre-dose04210
Remission Consolidation - 7 Days After Last Administration35553
Remission Consolidation - 14 Days After Last Administration35473
Remission Consolidation - 21 Days After Last Administration24452
SecondaryPlasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

Pharmacodynamics criterion.

Time frame:
7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
Reported as:
Count of participants · Participants
Plasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
ParticipantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Remission Induction - 7 Days After Last Administration961167
Remission Induction - 14 Days After Last Administration941054
Remission Induction - 21 Days After Last Administration85732
Remission Consolidation - Pre-Dose01000
Remission Consolidation - 7 Days After Last Administration35553
Remission Consolidation - 14 Days After Last Administration35462
Remission Consolidation - 21 Days After Last Administration24432
SecondaryPlasma Asparaginase Activity (PAA) Level ≥0.2 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

Pharmacodynamics criterion.

Time frame:
7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
Reported as:
Count of participants · Participants
Plasma Asparaginase Activity (PAA) Level ≥0.2 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
ParticipantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Remission Induction - 7 Days After Last Administration961044
Remission Induction - 14 Days After Last Administration83723
Remission Induction - 21 Days After Last Administration74600
Remission Consolidation - Pre-Dose00000
Remission Consolidation - 7 Days After Last Administration34552
Remission Consolidation - 14 Days After Last Administration34442
Remission Consolidation - 21 Days After Last Administration24422
SecondaryPlasma Asparaginase Activity (PAA) Level ≥0.4 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)

Pharmacodynamics criterion.

Time frame:
7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
Reported as:
Count of participants · Participants
Plasma Asparaginase Activity (PAA) Level ≥0.4 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)
ParticipantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Remission Induction - 7 Days After Last Administration86412
Remission Induction - 14 Days After Last Administration43100
Remission Induction - 21 Days After Last Administration22100
Remission Consolidation - Pre-Dose00000
Remission Consolidation - 7 Days After Last Administration34422
Remission Consolidation - 14 Days After Last Administration24311
Remission Consolidation - 21 Days After Last Administration24100
SecondaryPAA-derived Maximum Concentration (Cmax) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).

PAA-derived Cmax are based on population modeling analysis.

Time frame:
From days 4-25 (Remission Induction, Day 0-35 post baseline)
Reported as:
Mean · IU/L
PAA-derived Maximum Concentration (Cmax) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).
IU/LPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
PAA-derived Maximum Concentration (Cmax) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).970.0417 ± 224.09392818.8100 ± 121.418221043.6224 ± 194.66218579.5235 ± 171.48823580.4971 ± 101.79263
SecondaryPAA-derived Area Under the PAA-Time Curve From Time 0 to Day 35 (AUC 0-35) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).

PAA-derived AUC 0-35 are based on population modeling analysis.

Time frame:
From Days 0-35 (Remission Induction, Day 0-35 post baseline)
Reported as:
Mean · IU*hrs/L
PAA-derived Area Under the PAA-Time Curve From Time 0 to Day 35 (AUC 0-35) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).
IU*hrs/LPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
PAA-derived Area Under the PAA-Time Curve From Time 0 to Day 35 (AUC 0-35) After the Remission Induction Phase Day 4 Dose (Part 1 and 2).306482.6354 ± 102792.09776229404.0145 ± 71993.03662314100.2843 ± 83939.08866145811.0930 ± 65530.10010134979.0088 ± 45507.48622
SecondaryMinimal Residual Disease (MRD) at End of Remission Induction (Part 1 and 2)

Efficacy criterion. A positive result indicates that there is some disease still present. A negative result indicates that there is no disease present.

Time frame:
End of remission induction phase (Day 0-35 post baseline) (Day 29).
Reported as:
Count of participants · Participants
Minimal Residual Disease (MRD) at End of Remission Induction (Part 1 and 2)
ParticipantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Positive35334
Negative33212
Indeterminate00000
Not available11000
Not performed22142
SecondaryParticipants Who Achieved Complete Remission (CR) (Part 1 and 2)

Morphologic complete remission rate (CR), morphologic complete remission rate with incomplete blood count recovery (CRi).

Time frame:
Day 29 remission induction phase (Day 0-35 post baseline)
Reported as:
Count of participants · Participants
Participants Who Achieved Complete Remission (CR) (Part 1 and 2)
ParticipantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Participants Who Achieved Complete Remission (CR) (Part 1 and 2)66355
SecondaryEFS (Event-free Survival) (Part 1 and 2)

Probability estimates for EFS until 1 year, 2 years, and 3 years

Time frame:
Through study completion an average of 3.5 years
Reported as:
Number · Percentage of participants
EFS (Event-free Survival) (Part 1 and 2)
Percentage of participantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
1 yearNA (NA to NA)27.3 (6.52 to 53.89)33.3 (4.61 to 67.56)25.0 (3.71 to 55.81)12.5 (0.66 to 42.27)
2 yearsNA (NA to NA)27.3 (6.52 to 53.89)33.3 (4.61 to 67.56)25.0 (3.71 to 55.81)12.5 (0.66 to 42.27)
3 yearsNA (NA to NA)NA (NA to NA)33.3 (4.61 to 67.56)NA (NA to NA)NA (NA to NA)
SecondaryDFS (Disease-free Survival) (Part 1 and 2)

Probability estimates for DFS until 1 year, 2 years, and 3 years

Time frame:
Through study completion an average of 3.5 years
Reported as:
Number · Percentage of participants
DFS (Disease-free Survival) (Part 1 and 2)
Percentage of participantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
1 yearNA (NA to NA)66.7 (5.41 to 94.52)100.00 (100.00 to 100.00)75.0 (12.79 to 96.05)80.0 (20.38 to 96.92)
2 yearsNA (NA to NA)66.7 (5.41 to 94.52)100.00 (100.00 to 100.00)75.0 (12.79 to 96.05)80.0 (20.38 to 96.92)
3 yearsNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryOS (Overall Survival) (Part 1 and 2)

Probability estimates for OS until 1 year, 2 years, and 3 years

Time frame:
Through study completion an average of 3.5 years
Reported as:
Number · Percentage of participants
OS (Overall Survival) (Part 1 and 2)
Percentage of participantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
1 yearNA (NA to NA)85.7 (33.41 to 97.86)100.0 (100.00 to 100.00)62.5 (22.93 to 86.07)75.0 (31.48 to 93.09)
2 yearsNA (NA to NA)85.7 (33.41 to 97.86)100.0 (100.00 to 100.00)62.5 (22.93 to 86.07)75.0 (31.48 to 93.09)
3 yearsNA (NA to NA)NA (NA to NA)83.3 (27.31 to 97.47)62.5 (22.93 to 86.07)75.0 (31.48 to 93.09)
SecondaryAnti-drug (Calaspargase Pegol) Antibody (ADA) Development (Part 1 and 2)

Immunogenicity criterion.

Time frame:
Through 365 (±7) days after the first dose or 30 days after the last dose if the participant discontinued
Reported as:
Count of participants · Participants
Anti-drug (Calaspargase Pegol) Antibody (ADA) Development (Part 1 and 2)
ParticipantsPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Negative28552
Pre-existing positive21011
Treatment-boosted21101
Treatment-emergent31013

Adverse events

Collected over Through study completion, approximately 3.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 2: Calaspargase Pegol (S95015) 1750 U/m20/9 (0%)8/9 (88.9%)9/9 (100%)
Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m21/11 (9.1%)7/11 (63.6%)11/11 (100%)
Part 1: Calaspargase Pegol (S95015) 2000 U/m21/6 (16.7%)2/6 (33.3%)6/6 (100%)
Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)3/8 (37.5%)6/8 (75%)8/8 (100%)
Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)2/8 (25%)5/8 (62.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
Febrile neutropeniaBlood and lymphatic system disorders2/94/111/64/81/8
ThrombocytopeniaBlood and lymphatic system disorders0/90/110/62/80/8
HyperbilirubinaemiaHepatobiliary disorders0/90/110/62/80/8
Infusion related hypersensitivity reactionImmune system disorders2/90/110/60/80/8
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/90/110/60/81/8
PyrexiaGeneral disorders0/90/111/61/80/8
AnaemiaBlood and lymphatic system disorders0/90/110/61/80/8
Enterococcal infectionInfections and infestations0/90/110/61/80/8
Pneumonia bacterialInfections and infestations0/90/110/61/80/8
SepsisInfections and infestations0/90/110/60/81/8
Most frequent other events
Showing 10 of 196
Most frequent other events
EventPart 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)
NauseaGastrointestinal disorders5/95/115/65/82/8
HypoalbuminaemiaMetabolism and nutrition disorders2/94/114/61/82/8
HeadacheNervous system disorders4/97/113/61/83/8
AnaemiaBlood and lymphatic system disorders5/94/111/61/83/8
ConstipationGastrointestinal disorders1/96/111/63/83/8
White blood cell count decreasedInvestigations3/96/112/61/83/8
Blood fibrinogen decreasedInvestigations4/96/111/61/82/8
Oedema peripheralGeneral disorders1/96/112/62/81/8
Alanine aminotransferase increasedInvestigations1/95/112/62/84/8
Blood bilirubin increasedInvestigations1/94/111/61/84/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)Total
Mean25.9 ± 4.1747.5 ± 5.2230.3 ± 3.5664.1 ± 6.8540.1 ± 10.1642.2 ± 14.77
Sex: Female, Male
Sex: Female, Male(Participants)Part 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)Total
Female4823623
Male5345219
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)Total
White61146633
Black or African American200013
Asian001113
Native Hawaiian or Other Pacific Islander000000
American Indian or Alaska Native000000
Other101103
Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 2: Calaspargase Pegol (S95015) 1750 U/m2Part 1 and Part 2: Calaspargase Pegol (S95015) 1500 U/m2Part 1: Calaspargase Pegol (S95015) 2000 U/m2Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (≥ 55 Years)Part 1: Calaspargase Pegol (S95015) 1000 U/m2 (<55 Years)Total
Hispanic or Latino0433111
Not Hispanic or Latino8735730
Not reported000000
Unknown100001
08

Study locations

21 sites
  • HonorHealth Cancer Transplant Institute
    Scottsdale, Arizona 85258, United States
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Univeristy of California
    Los Angeles, California 90095, United States
  • University of California Irvine Health (UCI Health)
    Orange, California 92868, United States
  • University of Miami Health System - Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • University of Kansas Cancer Center - Richard and Annette Bloch Cancer Care Pavilion
    Westwood, Kansas 66205, United States
  • University of Maryland Greenbaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Dana Farber Cancer Institute
    Weymouth, Massachusetts 02190, United States
  • Northwell Health Cancer Institute
    Lake Success, New York 11042, United States
  • NYU Langone/Laura and Isaac Perlmutter Cancer Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health & Science University (OHSU)
    Portland, Oregon 97239, United States
  • Jefferson Health
    Philadelphia, Pennsylvania 19107, United States
  • Baptist Clinical Research Institute
    Memphis, Tennessee 38120, United States
  • Intermountain Healthcare (IHC)
    Salt Lake City, Utah 84143, United States
  • University of Washington/Seattle Cancer Care Alliance/Fred Hutch
    Seattle, Washington 98109, United States
  • West Virginia University Cancer Institute
    Morgantown, West Virginia 26506, United States
09

References and documents

Publications

  • Stock W, Park JH, Emadi A, Abdul-Hay M, Cassaday RD, Pullarkat VA, Webster J, Pandya SS, Mogul MJ, Shvenke Y, Zhu JJ, Tessier A, DeAngelo DJ. Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study. Blood. 2021 Nov 23;138(Supplement 1):4406. doi: https://doi.org/10.1182/blood-2021-149463
  • Aldoss I, Ali A, Cassaday RD, Curran EK, Luskin MR, Maese LD, Orgel E, Douer D. Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations. Am J Hematol. 2026 Jan;101(1):41-55. doi: 10.1002/ajh.70103. Epub 2025 Oct 11. PubMed 41074700 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorisation in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2021 to primary completion in Apr 2025, 44 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Mar 2025 → Apr 2025 and completion Mar 2025 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2021
First posted
Mar 26, 2021
StartActual
Jul 7, 2021
Primary completionActual
Apr 6, 2025was Mar 2025
CompletionActual
Apr 6, 2025was Mar 2025
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Why stopped
Sponsor decision.
Oct 29, 2026
Results
Results posted
posted Oct 29, 2026
Primary completion
Mar 21, 2025→Apr 6, 2025
Oct 29, 2026
Study completion
Mar 21, 2025→Apr 6, 2025
Oct 29, 2026
Eligibility
Maximum age 55 Years→none; 1 inclusion criterion edited; 1 exclusion criterion edited, 1 added, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedAged ≥22 and <55 years with newly-diagnosed and cytologically confirmed and documented Philadelphia-negative B-cell or T-cell ALL by World Health Organization (WHO) classification (2016).
Exclusion criteria
  • EditedKnown severe hepatic impairment (bilirubin >3 x upper limit of normal [ULN]; transaminases >105 times ULN (unless suspected leukemic involvement of the liver).
  • RemovedAge ≥ 55 years.
  • RemovedBMI > 35 kg/m2.
  • AddedBMI > 35 kg/m2 (This criterion was introduced as an amendment for Part 2)
Oct 29, 2026
Primary outcomes
2 edited, 1 time frame changed, 1 removed, 1 description edited
What changed in the outcomes
  • EditedAdverse Events (AEs) (Part 1)Time frame: From signing the ICF through 30 days after the Calaspargase pegol administration at Day 4 (or Day 5 or Day 6) in the Remission Induction phase. → Through study completion, approximately 3.5 years
  • EditedAdverse EventsPlasma Asparaginase Activity (AEsPAA) Level (Part 1 and Part 2)Time frame: From signing the ICF through 30 days after the last dose of the study drug in Delayed Intensification phase. → 7 days, 14 days, 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and the Remission Consolidation phase (Day 36-91 post baseline)
  • RemovedPlasma Asparaginase Activity (PAA) level (Part 1)Time frame: Days 4, 5, 6 (Remission Induction phase) for PAA samples. Days 11, 18, 25 (Remission Induction phase) for TDM samples.
  • Time frameNadir Plasma Asparaginase Activity (NPAA) (Part 2)Day 64 (Remission Consolidation Phase). → Day 64 (Remission Consolidation Phase Day 36-91 post baseline).
  • DescriptionNadir Plasma Asparaginase Activity (NPAA) (Part 2): how it is measured was reworded
Oct 29, 2026
Documents
Secondary outcomes
8 edited, 5 added
What changed in the outcomes
  • EditedNumber of Participants With Plasma Asparaginase Activity (PAA) levelLevel ≥0.1 U/mL at any time duringAny Time During Remission Induction phasePhase and postPost- Remission Induction phasePhase, respectivelyRespectively (Part 1 and Part 2)Time frame: Days 4-5-6 & 11-18-25 (Remission Induction); Days 15-16-43-44 & 22-29-36-50-57-64 (Consolidation); Days 22-23 & 29-36-43 (Interim Maintenance); Days 4-5,43-44 & 11-18-25-50-57-64 (Delayed Intensification) for PAA & TDM samples respectively. → Days 4-5-6&11-18-25 (Induction, Day 0-35 PB (post baseline)); Days 15-16-43-44&22-29-36-50-57-64 (Consolidation, Day 36-91 PB); Days 22-23&29-36-43 (Maintenance, Day 92-147 PB); Days 4-5,43-44 & 11-18-25-50-57-64 (Delayed Intensification, Day 148-203 PB)
  • EditedPlasma Asparaginase Activity (PAA) levelLevel ≥0.025, ≥0.1, ≥0.2, or ≥0.4 U/mL at predefined time points duringPredefined Time Points During Remission Induction phasePhase and postPost- Remission Induction phasePhase, respectivelyRespectively (Part 1 and Part 2)Time frame: Days 4-5-6 & 11-18-25 (Remission Induction); Days 15-16-43-44 & 22-29-36-50-57-64 (Consolidation); Days 22-23 & 29-36-43 (Interim Maintenance); Days 4-5-43-44 & 11-18-25-50-57-64 (Delayed Intensification) for PAA & TDM samples respectively. → 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
  • EditedPAA-derived maximum concentrationMaximum Concentration (Cmax) afterAfter the Remission Induction Phase Day 4 doseDose (Part 1 and 2).Time frame: Days 4, 5, 6 & 11, 18, 25 (Remission Induction); for PAA & TDM samples respectively. → From days 4-25 (Remission Induction, Day 0-35 post baseline)
  • EditedPAA-derived Area Under the PAA-Time Curve From Time 0 to Day 2135 (AUC 0-2135) afterAfter the Remission Induction Phase Day 4 doseDose (Part 1 and 2).Time frame: Days 4, 5, 6 & 11, 18, 25 (Remission Induction); for PAA & TDM samples respectively. → From Days 0-35 (Remission Induction, Day 0-35 post baseline)
  • EditedMinimal residual diseaseResidual Disease (MRD) at End of Remission Induction (Part 1 and 2)Time frame: End of remission induction phase (Day 29). → End of remission induction phase (Day 0-35 post baseline) (Day 29).
  • EditedParticipants Who Achieved Complete remissionRemission (CR) (Part 1 and 2)Time frame: Day 29 remission induction therapy → Day 29 remission induction phase (Day 0-35 post baseline)
  • EditedEFS (Event-free Survival) (Part 1 and 2)Time frame: Through study completion an average of 3 months. → Through study completion an average of 3.5 years
  • EditedAnti-drugDFS (calaspargase pegolDisease-free Survival) antibody (ADA) development (Part 1 and 2)Time frame: D4, D18, D29 (Remission Induction Phase), D15, D43 (Remission Consolidation Phase), D22 (Interim Maintenance Phase), D4, D43 (Delayed Intensification Phase), Day 365 (±7) after the first dose, Day 30 after the last dose if discontinuation. → Through study completion an average of 3.5 years
  • AddedPlasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
  • AddedPlasma Asparaginase Activity (PAA) Level ≥0.2 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
  • AddedPlasma Asparaginase Activity (PAA) Level ≥0.4 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
  • AddedOS (Overall Survival) (Part 1 and 2)Time frame: Through study completion an average of 3.5 years
  • AddedAnti-drug (Calaspargase Pegol) Antibody (ADA) Development (Part 1 and 2)Time frame: Through 365 (±7) days after the first dose or 30 days after the last dose if the participant discontinued
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Why stopped Sponsor decision.
    Results posted
    Primary completion Mar 21, 2025→Apr 6, 2025
    Study completion Mar 21, 2025→Apr 6, 2025
    Eligibility Maximum age 55 Years→none; 1 inclusion criterion edited; 1 exclusion criterion edited, 1 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedAged ≥22 and <55 years with newly-diagnosed and cytologically confirmed and documented Philadelphia-negative B-cell or T-cell ALL by World Health Organization (WHO) classification (2016).
    Exclusion criteria
    • EditedKnown severe hepatic impairment (bilirubin >3 x upper limit of normal [ULN]; transaminases >105 times ULN (unless suspected leukemic involvement of the liver).
    • RemovedAge ≥ 55 years.
    • RemovedBMI > 35 kg/m2.
    • AddedBMI > 35 kg/m2 (This criterion was introduced as an amendment for Part 2)
    Primary outcomes 2 edited, 1 time frame changed, 1 removed, 1 description edited
    What changed in the outcomes
    • EditedAdverse Events (AEs) (Part 1)Time frame: From signing the ICF through 30 days after the Calaspargase pegol administration at Day 4 (or Day 5 or Day 6) in the Remission Induction phase. → Through study completion, approximately 3.5 years
    • EditedAdverse EventsPlasma Asparaginase Activity (AEsPAA) Level (Part 1 and Part 2)Time frame: From signing the ICF through 30 days after the last dose of the study drug in Delayed Intensification phase. → 7 days, 14 days, 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and the Remission Consolidation phase (Day 36-91 post baseline)
    • RemovedPlasma Asparaginase Activity (PAA) level (Part 1)Time frame: Days 4, 5, 6 (Remission Induction phase) for PAA samples. Days 11, 18, 25 (Remission Induction phase) for TDM samples.
    • Time frameNadir Plasma Asparaginase Activity (NPAA) (Part 2)Day 64 (Remission Consolidation Phase). → Day 64 (Remission Consolidation Phase Day 36-91 post baseline).
    • DescriptionNadir Plasma Asparaginase Activity (NPAA) (Part 2): how it is measured was reworded
    Secondary outcomes 8 edited, 5 added
    What changed in the outcomes
    • EditedNumber of Participants With Plasma Asparaginase Activity (PAA) levelLevel ≥0.1 U/mL at any time duringAny Time During Remission Induction phasePhase and postPost- Remission Induction phasePhase, respectivelyRespectively (Part 1 and Part 2)Time frame: Days 4-5-6 & 11-18-25 (Remission Induction); Days 15-16-43-44 & 22-29-36-50-57-64 (Consolidation); Days 22-23 & 29-36-43 (Interim Maintenance); Days 4-5,43-44 & 11-18-25-50-57-64 (Delayed Intensification) for PAA & TDM samples respectively. → Days 4-5-6&11-18-25 (Induction, Day 0-35 PB (post baseline)); Days 15-16-43-44&22-29-36-50-57-64 (Consolidation, Day 36-91 PB); Days 22-23&29-36-43 (Maintenance, Day 92-147 PB); Days 4-5,43-44 & 11-18-25-50-57-64 (Delayed Intensification, Day 148-203 PB)
    • EditedPlasma Asparaginase Activity (PAA) levelLevel ≥0.025, ≥0.1, ≥0.2, or ≥0.4 U/mL at predefined time points duringPredefined Time Points During Remission Induction phasePhase and postPost- Remission Induction phasePhase, respectivelyRespectively (Part 1 and Part 2)Time frame: Days 4-5-6 & 11-18-25 (Remission Induction); Days 15-16-43-44 & 22-29-36-50-57-64 (Consolidation); Days 22-23 & 29-36-43 (Interim Maintenance); Days 4-5-43-44 & 11-18-25-50-57-64 (Delayed Intensification) for PAA & TDM samples respectively. → 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
    • EditedPAA-derived maximum concentrationMaximum Concentration (Cmax) afterAfter the Remission Induction Phase Day 4 doseDose (Part 1 and 2).Time frame: Days 4, 5, 6 & 11, 18, 25 (Remission Induction); for PAA & TDM samples respectively. → From days 4-25 (Remission Induction, Day 0-35 post baseline)
    • EditedPAA-derived Area Under the PAA-Time Curve From Time 0 to Day 2135 (AUC 0-2135) afterAfter the Remission Induction Phase Day 4 doseDose (Part 1 and 2).Time frame: Days 4, 5, 6 & 11, 18, 25 (Remission Induction); for PAA & TDM samples respectively. → From Days 0-35 (Remission Induction, Day 0-35 post baseline)
    • EditedMinimal residual diseaseResidual Disease (MRD) at End of Remission Induction (Part 1 and 2)Time frame: End of remission induction phase (Day 29). → End of remission induction phase (Day 0-35 post baseline) (Day 29).
    • EditedParticipants Who Achieved Complete remissionRemission (CR) (Part 1 and 2)Time frame: Day 29 remission induction therapy → Day 29 remission induction phase (Day 0-35 post baseline)
    • EditedEFS (Event-free Survival) (Part 1 and 2)Time frame: Through study completion an average of 3 months. → Through study completion an average of 3.5 years
    • EditedAnti-drugDFS (calaspargase pegolDisease-free Survival) antibody (ADA) development (Part 1 and 2)Time frame: D4, D18, D29 (Remission Induction Phase), D15, D43 (Remission Consolidation Phase), D22 (Interim Maintenance Phase), D4, D43 (Delayed Intensification Phase), Day 365 (±7) after the first dose, Day 30 after the last dose if discontinuation. → Through study completion an average of 3.5 years
    • AddedPlasma Asparaginase Activity (PAA) Level ≥0.1 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
    • AddedPlasma Asparaginase Activity (PAA) Level ≥0.2 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
    • AddedPlasma Asparaginase Activity (PAA) Level ≥0.4 U/mL at Predefined Time Points During Remission Induction Phase and Post- Remission Induction Phase, Respectively (Part 1 and Part 2)Time frame: 7 days, 14 days, and 21 days after last administration in the Remission Induction phase (Day 0-35 post baseline) and pre-dose, 7 days, 14 days, and 21 days after last administration in the Remission Consolidation phase (Day 36-91 post baseline)
    • AddedOS (Overall Survival) (Part 1 and 2)Time frame: Through study completion an average of 3.5 years
    • AddedAnti-drug (Calaspargase Pegol) Antibody (ADA) Development (Part 1 and 2)Time frame: Through 365 (±7) days after the first dose or 30 days after the last dose if the participant discontinued
    + 4 other changes: index terms, verification date, responsible party and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04817761
Lead sponsor
Institut de Recherches Internationales Servier
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
Jul 7, 2021
Primary completion
Apr 6, 2025
Completion
Apr 6, 2025
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Daniel J. DeAngelo, MD, PhD
principal investigator · Dana-Farber Cancer Institute, Boston, MA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calaspargase pegol

Start the discussion